Porownywarka
Desmopressin vs Oxytocin side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Desmopressin | Oxytocin |
|---|---|---|
| Kategoria | Hormonalne | Hormonalne |
| Znany tez jako | DDAVP, Stimate, Minirin | Pitocin, Syntocinon, The Love Hormone |
| Zatwierdzony przez FDA | Tak | Tak |
| Status kliniczny | FDA Approved - Multiple indications
| FDA approved for labor and postpartum use; other uses remain under research
|
| Czego oczekiwac | Bedwetting, diabetes insipidus, bleeding disorders | Social bonding, anxiety, trust, emotional wellbeing |
| Jak dziala | Desmopressin is described as a V2-selective vasopressin receptor agonist. In renal collecting ducts, V2 activation raises intracellular signaling that moves aquaporin water channels into place, allowing more water to be reabsorbed and producing smaller volumes of more concentrated urine. The source also notes that desmopressin has much less V1-mediated blood-vessel constriction than vasopressin. In endothelial tissue, V2 activity can increase release of stored von Willebrand factor and factor VIII, linking the same receptor system to hemostatic effects in selected bleeding disorders. | Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor described in the source as present in the uterus, breast tissue, and multiple brain areas including the amygdala. In peripheral tissues, signaling is linked to calcium-mediated uterine contraction and milk ejection. Central effects are described as modulation of fear, reward, and social-attention circuitry, but intranasal research is difficult to interpret because the amount reaching the brain is uncertain and may involve indirect pathways. |
| Typowe dawkowanie | Limited community data available · See research protocols | 10-24 IU intranasal as needed · As needed · Intranasal |
| Dawkowanie z badań | 10-40 mcg intranasal · Varies by condition · Intranasal, oral, IV, or subcutaneous | 10-40 IU IV for labor · Single dose or short-term use · IV (obstetric); intranasal (research) |
| Typowy czas trwania | Varies by condition | Single dose or short-term use |
| Podanie | Intranasal, oral, IV, or subcutaneous | IV in obstetric labeling; intranasal in research contexts |
| Timing | Morning or as directed With or without food | As needed in studied social or bonding contexts With or without food |
| Poziom dowodów | Zatwierdzone przez FDA | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+3 więcej
|
+4 więcej
|
| Podsumowanie researchu | The source characterizes desmopressin as a long-used approved medicine rather than an experimental peptide. It reports clinical relevance in central diabetes insipidus, nocturnal enuresis, and nocturia through reduced urine production. It also describes hemostatic use because desmopressin can raise von Willebrand factor and factor VIII, with relevance to von Willebrand disease, mild hemophilia A, and some procedure-related contexts. The main safety issue emphasized is dilutional hyponatremia from retained water, with higher concern in young children and older adults according to the supplied source. | The source treats injectable obstetric oxytocin as established, while describing intranasal behavioral research as contested. For social reward, a 2023 systematic review covering 19 randomized, double-blind, placebo-controlled studies and about 984 participants reported a clearer signal in brain-activity outcomes than in behavior or self-report. In autism research, the source cites a 2021 Scientific Reports randomized trial that did not find a substantial empathy-related neural activation change, and it notes that repeated-dose studies have ranged from modest social-behavior findings to no clear effect. Context and sex-specific differences are presented as important reasons the findings remain difficult to generalize. Short-term intranasal trial safety was described as reassuring, but the source does not establish a reliable clinical benefit for these investigational uses. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.